Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease.

ABSTRACT:

Objective

To demonstrate the effects of rituximab (RTX) in patients with rheumatoid arthritis-related interstitial lung disease (RA-ILD).

Methods

A total of 165 patients who used RTX for the management of rheumatoid arthritis were retrospectively scrutinised. Among these, 26 patients diagnosed with RA-ILD were analysed (61.5% male, mean age at RTX infusion 61.4 ± 6.5 years). To evaluate the efficacy of RTX on lung response, patients with pulmonary function test results and/or thorax computed tomography (chest-CT) of pre- and post-RTX were compared. Disease progression was defined as either a decline of ≥10% in forced vital capacity (FVC) and/or a decline of ≥15% in diffusion capacity of carbon monoxide (DLCO), or an increase of parenchymal involvement on chest-CT images acco

SUBMITTER: Sahin Eroglu D 

PROVIDER: S-EPMC9766850 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature